|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Vasculitis | |||||
| Wegener's Granulomatosis | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Wegener Granulomatosis | |||||
| 3 | More general conditions related to this trial | ||||
| Cardiovascular Diseases | |||||
| Kidney Diseases | |||||
| Lung Diseases | |||||
| Lung Diseases, Interstitial | |||||
| Respiratory Tract Diseases | |||||
| Urologic Diseases | |||||
| Vascular Diseases | |||||
| 4 | Interventions listed in this trial | ||||
| cyclophosphamide | |||||
| 5 | More general drug interventions related to this trial | ||||
| Alkylating Agents | |||||
| Antineoplastic Agents | |||||
| Antineoplastic Agents, Alkylating | |||||
| Antirheumatic Agents | |||||
| Immunologic Factors | |||||
| Immunosuppressive Agents | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Myeloablative Agonists | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| National Institute of Allergy and Infectious Diseases (NIAID) | |||||